TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Perceived cognitive deficits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in insulin resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breathlessness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate cancer (PCa) association
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Magnitude of nAb responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Epitope specificity of nAb responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of viral respiratory infections
Endpoint domain: Adverse events/effects
Primary endpoint: Posttraumatic symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of ulcers and erosions in the duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fentanyl requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fentanyl plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core endurance of lateral core muscle chains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Isometric strength of lateral core muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: self-care competence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: acute rejection rate
Endpoint domain: Adverse events/effects
Primary endpoint: time to first flatus passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: oral liquid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gastrointestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes
Endpoint domain: Mortality/survival
Primary endpoint: 5-year nonfatal myocardial infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall ICU mortality
Endpoint domain: Mortality/survival
Primary endpoint: extubation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilator weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete wound closure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Disease-free survival (DFS) events
Endpoint domain: Mortality/survival
Primary endpoint: Fat mass (FM) and intra-abdominal fat (IAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative epidural fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of posttraumatic stress symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonresponse status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores on diagnostic cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of watery diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relapse rate of diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC0‐24h of TDP in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of TDP in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax of TDP in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to exercise test (TET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgency of defecation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: patients' self-reported well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinical activity of ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of ablations needed for PVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum phosphorus concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: invasive breast cancer incidence
Endpoint domain: Mortality/survival
Primary endpoint: estrogen receptor positive invasive cancers incidence
Endpoint domain: Mortality/survival
Primary endpoint: ductal carcinoma in situ incidence
Endpoint domain: Mortality/survival
Primary endpoint: Resting VAS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum glycine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in baseline HAM-D17 score > or = 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically confirmed abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute myoPS increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ATPmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serotype-specific antibody concentrations >0.35 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sero conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitative CT objective evaluation in lung fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes-related quality of life (DRQoL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: subjective IKDC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TKS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to crutches discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in blood pressure to target levels (< 140/90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Recovery rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: time to onset of patchy mucosal reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor regression at treatment completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: acute mucositis of grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of sentinel lymph nodes (SLNs) removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SVV (Stroke Volume Variation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMS motor thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of symptomatic vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSI-attributable costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of surgical-site infections (SSIs)
Endpoint domain: Mortality/survival
Primary endpoint: evoked mechanical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPS activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hcy concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in tumour size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: verbal episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in frequency of symptoms attributable to ARTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in distress associated with symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of cesarean section (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in mFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean pocket reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defect resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACQL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Testicular volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rates of insulin rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean maximum acetylcholinesterase inhibition (Imax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas under the curve of acetylcholinesterase per cent inhibition (AUC0‐8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean HbA(1c) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of symptomatic hypoglycaemia events per patient-year
Endpoint domain: Adverse events/effects
Primary endpoint: Indinavir oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lamivudine-triphosphate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log10 changes in HIV-RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disturbance to sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Total antioxidant capacity (TEAC/UA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: procedure success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PANSS Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS Negative score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average deviation from target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of any coronary artery calcification (CAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Liver enzyme tests improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term FHR variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: record quality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recording time reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in plasma Zn concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in LDL-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of NCEP ATP III LDL-C target levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: End-systolic volume (ESV) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 2-day visual analog soreness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in Clinical Global Impression‐Bipolar scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization costs
Endpoint domain: Resource use
Primary endpoint: Resource utilization
Endpoint domain: Resource use
Primary endpoint: Reduction in plaque score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty-four hour urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of complete remission of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of complete remission of hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean distance base-out break
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean near base-out break
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean near phoria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall long-term survival
Endpoint domain: Mortality/survival
Primary endpoint: Reliability of Color Doppler Ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: brachial plexopathy risk
Endpoint domain: Adverse events/effects
Primary endpoint: amount of bone induced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of myocardial infarction, stroke, heart failure, and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Qs/Qt ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vasopressor requirements
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percentage reduction from baseline IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of elevated blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure control among treated individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: response strength scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV RNA <120 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ lymphocyte count increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Consecutive weeks of opioid-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life variables
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tegner Level of Activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum sTWEAK level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Coronary artery calcification (CAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of severe wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in tympanic membrane temperature from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol IAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with residual parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of apparent recrudescent infection by day 84
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical tolerance to parasitemia (absence of fever)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of rocuronium dose excreted unchanged in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite analyses of OA clinical endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total muscle CSA of both thighs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: wake time after sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate endocervical cell yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of cytologic atypia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate (spot bleeding and spontaneous abortion)
Endpoint domain: Adverse events/effects
Primary endpoint: noradrenaline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum total and low-density lipoprotein-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transcript expression of ACE and ACE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated messenger RNA expression of tumour necrosis factor α and interleukin‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum biomarkers IFN‐γ and IL‐10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual restoration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy follow-up rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective rate of whitening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: large arterial elasticity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of parastomal hernia formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Shoulder flexion range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive Breast Tumor (IBT) frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean percent reduction in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean percent reduction in noninflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of pain during radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms predicting subjective health complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Avoidance of activity and participation predicting fear avoidance behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Limitation in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in VMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal FBF after iron infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FBF response to glyceryl-trinitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: microcirculation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intravascular injection
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality at 180 days postrandomization
Endpoint domain: Mortality/survival
Primary endpoint: Survival at 12 years
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from chronic rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oncotype DX use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physician comfort with systemic therapy decisions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: flank pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bladder pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgency improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes